Resisting Resistance: Targeted Therapies in Lung Cancer

Trends in Cancer

Volumn 2, Issue 7, 2016, Pages 350-364

  Lin, Jessica J ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

drug resistance; non small cell lung cancer; tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE; ANIMAL; DRUG RESISTANCE; GENETIC HETEROGENEITY; GENETICS; LUNG TUMOR; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84990038489     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.05.010     Document Type: Review

References (95)

1. 1 Weinstein, I.B., Addiction to oncogenes – the Achilles heal of cancer. Science 297 (2002), 63–64.
2. 2 Camidge, D.R., et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11 (2014), 473–481.
3. 3 Maemondo, M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362 (2010), 2380–2388.
4. 4 Rosell, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
5. 5 Zhou, C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12 (2011), 735–742.
6. 6 Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11 (2010), 121–128.
7. 7 Sequist, L.V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31 (2013), 3327–3334.
8. 8 Wu, Y.L., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15 (2014), 213–222.
9. 9 Solomon, B.J., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371 (2014), 2167–2177.
10. 10 Kris, M.G., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
11. 11 Barlesi, F., et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387 (2016), 1415–1426.
12. 12 Swanton, C., Govindan, R., Clinical implications of genomic discoveries in lung cancer. N. Engl. J. Med. 374 (2016), 1864–1873.
13. 13 Takeuchi, K., et al. RET, ROS1, and ALK fusions in lung cancer. Nat. Med. 18 (2012), 378–381.
14. 14 Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
15. 15 Bergethon, K., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30 (2012), 863–870.
16. 16 Shaw, A.T., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371 (2014), 1963–1971.
17. 17 Awad, M.M., et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J. Clin. Oncol. 34 (2016), 721–730.
18. 18 Oxnard, G.R., et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J. Thorac. Oncol. 8 (2013), 179–184.
19. 19 Arcila, M.E., et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 12 (2013), 220–229.
20. 20 Yang, J.C., et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 16 (2015), 830–838.
21. 21 Yasuda, H., et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med., 2013, 10.1126/scitranslmed.3007205.
22. 22 Yu, H.A., et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann. Oncol. 25 (2014), 423–428.
23. 23 Su, K.Y., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30 (2012), 433–440.
24. 24 Costa, C., et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin. Cancer Res. 20 (2014), 2001–2010.
25. 25 Turke, A.B., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17 (2010), 77–88.
26. 26 Karachaliou, N., et al. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci. Rep., 2015, 10.1038/srep17499.
27. 27 Nie, W., et al. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis. Oncotarget 6 (2015), 25696–25700.
28. 28 Bivona, T.G., et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471 (2011), 523–526.
29. 29 Byers, L.A., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19 (2013), 279–290.
30. 30 Park, K.S., et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J. Clin. Invest. 124 (2014), 3003–3015.
31. 31 Sholl, L.M., et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J. Thorac. Oncol. 8 (2013), 322–328.
32. 32 Jabbour, E.J., et al. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin. Lymphoma Myeloma Leuk. 13 (2013), 515–529.
33. 33 Sequist, L.V., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 2011, 10.1126/scitranslmed.3002003.
34. 34 Yu, H.A., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247.
35. 35 Arcila, M.E., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17 (2011), 1169–1180.
36. 36 Yun, C.H., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 2070–2075.
37. 37 Bean, J., et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14 (2008), 7519–7525.
38. 38 Balak, M.N., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12 (2006), 6494–6501.
39. 39 Costa, D.B., et al. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J. Clin. Oncol. 26 (2008), 1182–1184.
40. 40 Thress, K.S., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
41. 41 Ercan, D., et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin. Cancer Res. 21 (2015), 3913–3923.
42. 42 Yu, H.A., et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 1 (2015), 982–984.
43. 43 Niederst, M.J., et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21 (2015), 3924–3933.
44. 44 Choi, Y.L., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363 (2010), 1734–1739.
45. 45 Sasaki, T., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71 (2011), 6051–6060.
46. 46 Katayama, R., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med., 2012, 10.1126/scitranslmed.3003316.
47. 47 Doebele, R.C., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18 (2012), 1472–1482.
48. 48 Ignatius Ou, S.H., et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J. Thorac. Oncol. 9 (2014), 549–553.
49. 49 Fontana, D., et al. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med. 4 (2015), 953–965.
50. 50 Zou, H.Y., et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28 (2015), 70–81.
51. 51 Shaw, A.T., et al. Resensitization of crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374 (2015), 54–61.
52. 52 Awad, M.M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368 (2013), 2395–2401.
53. 53 Drilon, A., et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin. Cancer Res. 22 (2016), 2351–2358.
54. 54 Song, A., et al. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer. Clin. Cancer Res. 21 (2015), 2379–2387.
55. 55 Russo, M., et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 6 (2016), 36–44.
56. 56 Tabara, K., et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE, 2012, 10.1371/journal.pone.0041017.
57. 57 Niederst, M.J., et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun., 2015, 10.1038/ncomms7377.
58. 58 Katayama, R., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 7535–7540.
59. 59 Engelman, J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
60. 60 Yano, S., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68 (2008), 9479–9487.
61. 61 Gouji, T., et al. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?. J. Thorac. Oncol., 2014, 10.1097/JTO.0000000000000113.
62. 62 Lovly, C.M., et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 20 (2014), 1027–1034.
63. 63 Crystal, A.S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346 (2014), 1480–1486.
64. 64 Ohashi, K., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), E2127–2133.
65. 65 Cheung, H.W., et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 1 (2011), 608–625.
66. 66 De Bruin, E.C., et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 4 (2014), 606–619.
67. 67 Davies, K.D., et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE, 2013, 10.1371/journal.pone.0082236.
68. 68 Queirolo, P., et al. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat. Rev. 41 (2015), 519–526.
69. 69 Lin, L., et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E748–757.
70. 70 Trickler, E.M., et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov. 5 (2015), 960–971.
71. 71 Hrustanovic, G., et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21 (2015), 1038–1047.
72. 72 Miyamoto, S., et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jap. J. Clin. Oncol. 46 (2015), 170–173.
73. 73 Fujita, S., et al. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J. Thorac. Oncol., 2016, 10.1016/j.jtho.2015.12.105.
74. 74 Takegawa, N., et al. Transformation of ALK rearrangement-positive adenocarcinoma to small cell lung cancer in association with acquired resistance to alectinib. Ann. Oncol. 27 (2016), 953–955.
75. 75 Singh, A., Settleman, J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29 (2010), 4741–4751.
76. 76 Kim, H.R., et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol. Oncol. 7 (2013), 1093–1102.
77. 77 Zhang, Z., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44 (2012), 852–860.
78. 78 Zhou, J., et al. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget. 6 (2015), 44332–44345.
79. 79 Wilson, C., et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget 5 (2014), 7328–7341.
80. 80 Sharma, S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 (2010), 69–80.
81. 81 Bivona, T.G., Doebele, R.C., A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22 (2016), 472–478.
82. 82 Blakely, C.M., et al. NF-κB activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 11 (2015), 98–110.
83. 83 Obenauf, A.C., et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520 (2015), 368–372.
84. 84 Ramirez, M., et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun., 2016, 10.1038/ncomms10690.
85. 85 Hata, A.N., et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22 (2016), 262–269.
86. 86 Jänne, P.A., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699.
87. 87 Piotrowska, Z., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5 (2015), 713–722.
88. 88 Chaft, J.E., et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res. 17 (2011), 6298–6303.
89. 89 Browning, E.T., et al. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J. Thorac. Oncol., 2013, 10.1097/JTO.0b013e31827a892c.
90. 90 Chmielecki, J., et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med., 2011, 10.1126/scitranslmed.3002356.
91. 91 Chong, C.R., Jänne, P.A., The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19 (2013), 1389–1400.
92. 92 Kim, D.W., et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol., 2016, 10.1016/S1470-2045(15)00614-2.
93. 93 Shaw, A.T., et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 17 (2016), 234–242.
94. 94 Ou, S.H., et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J. Clin. Oncol. 34 (2016), 661–668.
95. 95 Awad, M.M., Shaw, A.T., ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol. 12 (2014), 429–439.